In S. aureus, the operon consists of two transcription units, termed agrBDCA and RNAIII (for reviews see [9] or [10] ).
These are driven by regulatory proteins which bind to promoters termed P2 and P3, thereby permitting RNA polymerase to transcribe the DNA into mRNA prior to translation of agr mRNA into proteins at the ribosomes. The P2 transcript consists of four genes that are transcribed and translated to give the four proteins AgrB, AgrD, AgrC and AgrA. AgrB is a transmembrane protein and is involved in the post-translational conversion of the membrane-anchored AgrD pro-peptide into a cyclic peptide QS signal molecule termed an autoinducing peptide (AIP). The AIP is secreted into the external environment of the cell [11] where it is sensed by the transmembrane AgrC protein which acts as the receptor of the TCS by binding to free AIP molecules [12] . This is an effective method of estimating population size or density since bacterial numbers will, to a certain extent, correlate with the level of AIP molecules in the immediate environment of the S. aureus cells. Bound AgrC then activates AgrA, the response regulator [9] , via a phosphorylation cascade. Activated AgrA has a higher affinity than non-activated AgrA for the DNA binding sites situated at the two promoters P2 and P3. The P2 promoter controls the agr genes, so a positive feedback loop, see Figure 1 , is created. The P3 transcript is a regulatory RNA termed RNAIII [13] which directs the increased translation of secreted virulence factors and repression of surface protein production [14] . The presence of enough activated AgrA thus leads to a switch in the behaviour of the population, from what we will call a down-regulated state to an up-regulated one. In other bacteria, the agr operon largely takes on this form, though the specific agr-induced responses differ.
The emergence of multi-antibiotic resistant S. aureus (including methicillin-and vancomycin-resistant S. aureus;
MRSA and VRSA respectively), enterococci and Clostridium difficile means that understanding the virulence mechanisms employed by these pathogens to cause diseases should aid the development of novel therapies to combat infection through attenuation of virulence. This may be achieved either through the prevention of virulence factor action or by blocking virulence factor production. With respect to the latter, the inhibition of QS offers one potential therapeutic strategy which is already evident in S. aureus since some strains were found to interfere with QS in others, a process sometimes referred to as quorum quenching. This is because within the staphylococci, agr polymorphisms occur; S. aureus has four different specificity groups with distinct AIPs and AgrC sensor domains and cross group AIP-AgrC interactions are inhibitory. Furthermore, intra-group activation and inter-group inhibition are both mediated exclusively by the same group-specific AgrC receptor [5, 6] . Thus while the AIPs from different S. aureus groups are sufficiently similar that they will bind to the AgrC receptor proteins of any other strain, they cannot activate the sensor protein and so block activation by the endogenous AIP. Thus intracellular AgrA will not become activated so effectively blocking the QS loop and forcing the fells into, or maintaining them in, a down-regulated state. Staphylococcus epidermidis also employs an agr operon in its regulation of virulence factor production [15] and it is demonstrated in [16] that its AIP is a potent inhibitor of the agr systems of three of the S. aureus groups and, conversely, AIP-4 inhibits that of S. epidermidis, suggesting that AIP-4 may have evolved to compete with S. epidermidis. We include in our model an inhibitor therapy which capitalises on this natural cross-inhibition by S. aureus: synthetic inhibitor molecules have been designed to block the QS loop of any strain of S. aureus [17] , thus downregulating them and potentially providing the immune system with a greater chance of eradicating the bacteria (see [18] or [19] for reviews of this concept). Experimental work has confirmed the potential success of this approach -see for example [20] , where a murine S. aureus skin abscess infection caused by a strain producing AIP-1 could be prevented by coadministering AIP-2. Since the therapy would not directly kill the bacteria, the chance of resistance developing is greatly reduced in comparison with antibiotic treatment.
While much work has been done on defining the molecular basis by which the agr system operates, a question mark remains over the mechanisms governing the TCS in all strains and species that use agr. Although it is clear which proteins play the role of receptor and response regulator, it is not always evident how the phosphorylation cascade occurs; in [21] , the phosphorylation cascade of the agr operon has been highlighted as one of the important open questions requiring investigation before the QS system can be fully exploited for therapeutic gain. In a classical TCS, AgrC would autophosphorylate on binding to an AIP molecule and then transfer this phosphate to AgrA, making the phosphorylated form of this protein the activator of the system. It has recently been shown in laboratory derivatives of S. aureus, that AgrC does indeed autophosphorylate [22] , implying that in this case, it is a classical TCS in operation. However, given the variety of TCSs in existence [2] , suggestions that both AgrA and AgrC could be phosphorylated constitutively in [9] and evidence that AgrA can bind the relevant DNA binding site in either its phosphorylated or unphosphorylated forms (though it has a higher affinity in the former case) in [23] open up the possibility that the phosphorylation cascade may vary within and between strains depending on the nature of the TCS. Given the ease of testing different hypotheses with mathematical models, as compared with experimental work and, given the prevalence of similar TCSs performing a variety of roles in different bacteria, we investigate in some detail three possibilities for the phosphorylation cascade:
I the agr operon employs a classical TCS; II AgrA is constitutively phosphorylated (so in this case dephosphorylated AgrA is the activator which binds to the DNA); III transmembrane AgrC is constitutively phosphorylated (and phosphorylated AgrA is the activator which binds to the DNA).
We examine the effect of inhibition with synthetic antagonists on the QS systems governed by each of these three scenarios, presenting time-dependent numerical solutions and bifurcation diagrams showing the response to changes in inhibitor therapy dosage for each of the three models. We are thus able to make comparisons between the three cascade mechanisms, demonstrating that the model assuming AgrA to be constitutively phosphorylated (Model II) is the most sensitive to inhibitor therapy, followed by Model III (which assumes transmembrane AgrC to be phosphorylated in the absence of AIP molecules), with the classical TCS cascade being the most robust. Additionally, we give asymptotic approximations to the steady-state solutions in order to clarify which reactions govern the behaviour of the cells in both the down-regulated and up-regulated states, to give analytical expressions for the threshold levels of inhibitor and to highlight simplified models which could be used for further analysis. These results provide a characterisation of when inhibitor therapy may be successful if the phosphorylation cascade is known; conversely, given suitable experimental data, they may aid the identification of which phosphorylation cascade is dominant in a given strain or species.
Model formulation
This work is an extension of our previous model in [24] , which treated the entire agr operon in the absence of inhibitor molecules. We performed a time-dependent asymptotic analysis on the model, focusing on the feedback loop, in order to investigate the roles of the various interactions which make up the QS system and monitor how a population of S. aureus may shift from a relatively harmless state to a highly virulent one. To our knowledge, the only other mathematical model of the agr operon is [25] (also focusing on S. aureus) which isolates the TCS (taken to be of the classical form) and examines the effect of SarA, another protein involved in the regulation of virulence factors, on the TCS. In the interests Model I follows the classical TCS, as described in §1. Model II allows for the possibility that AgrA is constitutively phosphorylated and consequently it is dephosphorylated AgrA which takes on the role of activator of the agr operon.
Model III assumes that transmembrane AgrC is phosphorylated in the absence of AIP -upon binding to an AIP molecule it transfers this phosphate to the AgrA protein.
of brevity, we do not provide the full details of the derivation of the formulations of our three models in this paper (they can be found in both [24] and [26] , the latter also containing further details of what follows). We instead focus on the assumptions required to differentiate between the three models. Figure 2 illustrates the different phosphorylation cascades and the following is a summary of the differences.
• Model I
In the case of a classical TCS, once a receptor has bound to an AIP molecule (at a rate β) it can autophosphorylate. To simplify the system we will assume that this process is sufficiently fast that it in effect happens as soon as the receptor binds to the AIP molecule. When the receptor transfers its phosphate to the AgrA protein (at a rate φ) it is free to autophosphorylate again, and the phosphorylated AgrA is able to bind to the promoter site of the DNA and upregulate mRNA transcription.
• Model II AgrA is phosphorylated constitutively by kinases at a rate ψA. We assume that when an AIP molecule binds to a receptor, the latter phosphorylates by removing the phosphate from AgrA (again, we assume that this occurs sufficiently fast that it effectively happens as soon as the receptor binds to the AIP), and this dephosphorylated AgrA is then free to bind to the promoter site of the DNA. We assume that the receptor can obtain a phosphate only from AgrA and not from any other source within the cell; this is required to isolate the TCS from influences outside of the agr loop and would reflect specificity of the protein structure.
• Model III Model III assumes that once AgrC has become transmembrane it can autophosphorylate at a rate ψR. Only when it is bound to an AIP molecule can it transfer this phosphate to an AgrA protein, and only phosphorylated AgrC is able to bind to AIP or to inhibitor molecules. Dephosphorylated AgrC cannot re-phosphorylate while still bound to an AIP molecule. We therefore need to distinguish between AIP-bound phosphorylated and dephosphorylated receptors, as well as unbound phosphorylated and non-phosphorylated receptors, and so extra variables are required for this third scenario. (In Models I and II, receptors are able to re-phosphorylate while still bound to an AIP molecule so these additional variables are not required.) We assume that housekeeping dephosphorylation of transmembrane AgrC is not required since it will not directly affect the level of activator (phosphorylated AgrA) in the cells: if a cell has reached an active state, but then all the AIP is washed away from the cell's environment, housekeeping dephosphorylation of AgrA will aid restoration of the cell to an inactive state; however, housekeeping dephosphorylation of transmembrane AgrC would not alter activator level once AIP is no longer present.
In all the models we assume that AIP-and inhibitor-bound receptors can spontaneously separate [27] , at rates γ and γi respectively and that AgrA is subject to housekeeping dephosphorylation. We assume that proteins are present at a large enough level to make a continuous approximation appropriate and that the population is well-mixed, so that spatial effects can be neglected. Mass-action expressions are used for all the reaction kinetics -these equations are, for conciseness, shown only in Figures 3, 4 and 5; see Tables 1 and 2 for definitions of variables and parameters and Appendix A for the default initial conditions (these being the naturally down-regulated steady states of the system in the absence of inhibitor molecules; in §3 we also use the initial conditions near the unstable steady state of the full systems in order to examine their bistability). [24] : AIP-bound receptor in its phosphorylated form is denoted R * P in this work rather than simply R * .
We do not consider the possibility that both AgrA and AgrC are constitutively phosphorylated as there would then be no phosphate transfer between the two, meaning that there could be no signal transduction. The three models presented here thus complete the possibilities for the TCS, allowing for a thorough investigation of the different cases.
Whilst most equations follow directly from conventional kinetic theory, that describing the proportion of up-regulated cells is less intuitive and for this we adopt a standard approach used in modelling gene regulation, see for example [28] .
Assuming that the activator protein can bind to, and subsequently separate from, a promoter site, the rate of change of the probability that a promoter site is bound (for our purposes this is equivalent to the proportion of agr up-regulated cells)
is given by Tables 1 and 2 for definitions of the variables and parameters. The dimensionless version of this model is shown in Figure 6 . The dashed and dotted boxes contain respectively the equations which change for Model II and for Model III. The arrows illustrate the direction of the positive feedback loop. Tables 1 and 2 for definitions of variables and parameters and Figure 7 for the dimensionless version. Tables 1 and 2 for the definitions of variables and parameters and Figure 8 for the dimensionless version.
for Models I and III, and in Appendix A and further information can be found in [24] and [26] .
As discussed in [24] , we do not have sufficient data for full parametrisation of the models. However, we do have enough information to estimate their relative sizes and, given the qualitative nature of our investigations, this is sufficient.
We here list our parameter scalings, but more details can be found in [24, 26] (we remark that certain definitions of nondimensional parameters differ in [24] , notably η, kS, φ and ka, with ki and βi being new parameters introduced in this study, making the equations superficially different whilst essentially being the same; this is largely due to a minor 
. Figure 8 : A schematic representation of the section of the nondimensional model of the agr circuit with synthetic inhibition which changes from Model I for Model III. We have scaled the parameters according to (4), (5) and (7).
alteration in the parameter scalings, namely that of kS, which is outlined below). We set ourselves up to apply asymptotic techniques by estimating relative sizes of the nondimensional parameters, our overall parameter choice being motivated by a desire to ensure that the mathematical analysis be revealing as well as biologically plausible. For instance, fundamental to our parameter choice is the ratio of basal transcription to QS-controlled transcription (m/v). To ensure that the cells can 'switch' between an up-regulated and down-regulated state, rather than this transformation being gradual (which would be contrary to the concept of a quorum), this ratio must be small. We thus define our basic small parameter as
where ǫ << 1 (this is consistent with previously published models of QS, for example [29] [30] [31] ), and scale
The first follows directly from (3) while the latter two stem from the assumption that signal binding to receptors is fast in comparison to basal transcription and degradation or translation of proteins (see the nondimensional definitions of these parameters given by (29) in Appendix A). We remark that smaller choices of v ′ result in the bacteria being unable to achieve a fully up-regulated state even in the absence of inhibitor, while choosing β ′ this large enables a rapid switch between active and inactive states [24] .
We choose our largest parameters to be the rates of AIP production and constitutive AgrA phosphorylation:
The scaling for ka follows from examination of the dimensional parameters which form ka:
(X is the initial condition of X given by (22) , for X = A, T, R, S) where we see that ka has a higher ratio of rates of activation to those of degradation and basal transcription than either v ′ , β ′ or β ′ i and it is therefore logical to take ka to be larger than either of these three nondimensional parameters. Choosing ka to be O(ǫ −2 ) also ensures that, at all times and regardless of how active the cells are initially, enough AIP will be produced (in the absence of any QS inhibition) to upregulate the cells if it is retained within their environment. Constitutive AgrA phosphorylation appears only in Model II and is chosen to be O(ǫ −2 ) to ensure that that there is not enough activator present in the absence of AIP for the cells to be activated. Additionally, this scaling ensures that Model II displays bistability: a number of the QS systems previously studied demonstrate bistable behaviour (see [25, 30, 32] for example), whereby in a certain parameter regime whether the cells reach an up-regulated or a down-regulated state depends upon the initial conditions. Choosing ψA to be
results in such bistable behaviour. Hence, both mathematically and biologically, it is logical to choose ψA to be large.
Finally, we choose two of the nondimensional parameters to be O(ǫ). These are µ ′ = ǫμ, and kS = ǫkS.
The first represents the rate of housekeeping dephosphorylation of AgrA and we assume that the bacteria can eliminate unwanted phosphorylated AgrA via degradation and dilution sufficiently efficiently to make little of this housekeeping process required. In [24] we used kS = O(1) in order to simplify the asymptotics; however, we here return to the biologically-motivated scaling employed in [26] . The implication of kS being O(ǫ) is that AgrD is rapidly turned over in the production of AIPs and reflects the efficiency of the signalling system.
For the timebeing, we leave ki, the source of inhibitor molecules (corresponding to their entry into the environment of the cells) as O(1). We will investigate how large this parameter must be to make synthetic inhibitor therapy effective for each of the three models. Unless otherwise stated, all dimensionless parameters in our numerical solutions (except ǫ) will be taken to be unity, with ǫ = 10 −2 . Table 3 displays the default parameter set with the scaled parameters displayed in their non-hatted form in order to be able to see their relative magnitudes. In [24, 26] we were able to demonstrate through a time-dependent asymptotic analysis that for this parameter choice, each of the reactions involved in upregulating the agr operon will appear in the leading-order behaviour of the system in the sequence expected from biological knowledge.
Thus the parameters are biologically realistic in addition to ensuring that the equations are amenable to asymptotic analysis.
Nondimensional parameter Default value Table 3 : The default parameter set. In this work, we concentrate on examining the effects of varying the rate k i at which inhibitor is introduced to the cells. Table 3 . While the three cases are qualitatively similar, Model I requires a much larger value of k i than the other two models to guarantee downregulation and it is thus the least sensitive to suppression by inhibitor. In this respect,
Model II has the weakest of the three cascades, as it can (for our parameter set) be suppressed with the lowest value of k i .
We investigate why this might be the case in the context of time-dependent solutions of the three models.
Numerical solutions
Our aim is to investigate the effects of inhibitor therapy on the three different cascades of the TCS. We begin by looking at the steady-state profile of P , the proportion of up-regulated cells, as we vary ki, i.e. the rate, per unit volume and time, at which inhibitor molecules are introduced into the environment of the cells. Figure 9 illustrates the resulting solution curves using our default parameter set; the solid lines represent stable steady states, the dashed lines unstable ones and the dotted lines track the asymptotic approximation to these curves which will be derived in §4.
Each model exhibits three regimes of steady-state behaviour. For lower values of ki there is not enough inhibitor to block the QS systems and the cells will always reach an up-regulated state (as in [24] , where ki = 0). For sufficiently large values of ki, there is enough inhibitor present to downregulate the cells whatever the initial state. Intermediate values of ki give bistability, so that the success of inhibitor therapy will be dependent upon the initial conditions of the system, notably on the level of upregulation of the population when the inhibitor is first applied (the position of the unstable branch gives some indication of the basins of attraction): if the operon is in the early stages of self-activation then inhibitor therapy stands a chance of blocking enough receptors to downregulate the operon; however, if the cells have already reached a sufficiently active state at the time that inhibitor molecules are introduced, the receptors will already be predominantly bound to AIP and the inhibitor will be unable to bind to enough receptors to prevent the cells from reaching an active state, albeit one with a slightly reduced level of activity from when no inhibitor is present. This hysteretic behaviour is consistent both with results derived in [25] and with experimental results which illustrate that the crucial step of staphylococcal murine abscess formation is in the initial stages of infection [33] : blocking the agr operon with inhibitor molecules during this early phase alone (the half-life of the inhibitor molecules, which are introduced only at the start of the experiment, is short in comparison with the length of time it takes to cause an infection) is sufficient to render the bacteria incapable of forming the abscess as the mice gain increased time to fight the weakened bacteria.
While each of the three cases produces this hysteresis curve, their bistable intervals correspond to considerably different ranges of ki. Model II has the smallest range and smallest upper and lower limits on the bistable region, followed by Model III and then Model I. Models I and II differ to such an extent that their bistable regions do not overlap. This suggests that the classical TCS cascade, represented by Model I, is more robust to inhibitor therapy than either of the other two, since a much larger value of ki is required before the inhibitor therapy can have any chance of success. Model II on the other hand, would be most sensitive to the inhibitor and therefore would be the least effective (in the current context) TCS cascade to have evolved in the agr operon of the three proposed here. It must be remembered, however, that care is needed when making comparisons between the three models, given that each contains parameters which do not appear in v, the models do not have bistable behaviour and so for a specific value of k i there will exist only one stable steady state.
Our parameter choice (v = 100) is consistent with previous mathematical and experimental results which suggest that the agr operon is likely to display bistable behaviour. the others. Nevertheless, if the appropriate data were available such differences would provide some insight into which phosphorylation cascade operates in such TCSs, in particular given the striking difference in the bistable region between Model I and Model II, allowing greater knowledge of when inhibitor therapy may and may not be successful.
We can also track the location of the fold bifurcations as we vary specific parameters (this we do using the package XPPAUT 5.91). For example, Figures 10 and 11 illustrate the fold locations as we vary the parameters v and ψA respectively (these parameters are in their unscaled but nondimensional form, as defined in (29)). We choose these parameters to emphasise the mathematical significance of our parameter choice (which in these figures corresponds to v = 100 and ψA = 10 4 ). We recall that v represents the ratio of the QS-controlled transcription rate to the basal rate, and ψA represents the rate of constitutive AgrA phosphorylation (in Model II only). For biological reasons we expect both of these parameters to be large (see §2). In each case, the shaded area represents the parameter regime that displays bistable behaviour. So, for example, for sufficiently small v the fold bifurcations are absent and only a single stable steady state is possible for any given value of ki. Our parameter choice is therefore consistent with the idea that the agr operon would display hysteretic behaviour. Notice that the lower fold in each case varies much less with ki than does the upper one.
The implication of this is that the higher the value of v the larger the bistable region will be, i.e. the minimum value of ki Figure 11 : Parameter plot of the fold locations for Model II with varying k i and ψ A , the latter parameter representing the rate of constitutive AgrA phosphorylation (we recall that this parameter appears only in Model II). As in Figure 10 , the left edge of the shaded area corresponds with the lower fold bifurcation and the right edge with the upper fold bifurcation.
Our parameter choice (ψ A = 10 4 ) is consistent with previous mathematical and experimental results which suggest that the agr operon is likely to display bistable behaviour.
at which it is possible for the inhibitor to downregulate the cells does not change markedly (at least relative to the upper fold) while the minimum value of ki required to guarantee downregulation increases greatly with v. Thus increasing the ratio of the rates of QS-controlled transcription to basal transcription is indicative of the cells augmenting their ability to self-activate in spite of the inhibitor. Conversely, decreasing ψA (see Figure 11 ) increases this bistable range because more non-phosphorylated AgrA (which is active) will be present in the cells merely because the act of constitutive phosphorylation is slower and not because more has been activated via the phosphorylation cascade. Such comments illustrate how results can be dependent upon parameter choice. For example, taking a sufficiently low value of ψA in Model II induces a bistable region comparable with those of Models I and III (although we believe this likely to be biologically inappropriate since activator would be present in the absence of AIP). In spite of the parameter-dependency, this type of comparison enables us to envisage when inhibitor therapy would be successful and how much would be required for each TCS cascade; in §4 we derive analytical expressions for this threshold level. in Models I and III the level of inactive AgrA (i.e., non-phosphorylated AgrA in these cases) decreases to much less than that of active AgrA, and any increase due to synthesis can be seen only early on when the QS loop has yet to take full effect. This increase is much more evident in Model III (see Figure 14(a) ). In Model II inactive AgrA is of the phosphorylated form and we see in Figure 13 (a) that in this instance the steady state levels of active and inactive AgrA are roughly the same due to the balance between phosphorylation on production and dephosphorylation via activation.
We see in Figure 13 (b) that once inhibitor is introduced this balance tips in favour of inactive AgrA, since the inhibitor molecules induce lower levels of activation. In each case, the level of unbound receptors decreases dramatically as more and more become bound to AIP molecules. Notice that Model I is the quickest to reach upregulation, followed by Model III and then Model II, i.e. it would seem likely that the sensitivity of the TCS to inhibition is linked to the time the cell takes to become active: the longer this process takes, the more opportunity there is for the inhibitor to suppress the agr operon and the larger the bistable region will be. and III we have adjusted the y-axis to illustrate clearly the difference between the upper stable branch and the lower two branches. Even so, the drop in the level ofR * P as ki increases is so drastic for these two models that it is impossible to distinguish between the unstable branch and the lower stable branch in these diagrams.
Asymptotic approximation to the steady-state curves
The full steady states of the three models cannot be expressed explicitly; instead, we exploit asymptotic techniques to derive approximations to the steady-state curves of Figure 9 (the approximations are given by the dotted lines) and the corresponding curves for all variables. The approximations are provided in this section, while, for conciseness, their derivations are given only in Appendix B. The scalings of ki and each variable needed to produce the asymptotic approximation to the active and unstable branches are denoted by X † ; when they are scaled to approximate the inactive branch we use X ‡ . The steady-state approximations for each variable X are denotedX † andX ‡ .
An asymptotic approach enables the inference of more precise information from the models than could be obtained by examining the numerical solutions in isolation. For instance, for each model we obtain analytical estimates of the Figure 16 : The real and positive roots of equations (a) (9) and (b) (11) . These approximate (a) the active stable branch, unstable branch and upper fold bifurcation, and (b) the inactive stable branch and lower fold bifurcation of the solution curve for Model I given in Figure 9 (a). In (c) we plot the asymptotic approximations with the full numerical solutions.
threshold levels of inhibitor required for it to be successful in downregulating the agr operon (both possible success, initial conditions permitting, and guaranteed success), providing insight into which parameters are predominantly responsible for the efficacy of inhibitor therapy.
Model I

Active stable branch and unstable branch
The asymptotic approximations to the active stable branch and unstable branch are given bȳ
where the possible leading-orderP † are given by the physically-meaningful roots of
(we note that the approximations forB,C,D andT here, and henceforth, are identical to that ofM ). It is noteworthy that the gene expression level is fully under the control of the QS loop, basal transcription being negligible (seeM † ∼vP † in (8)).
Equation (9) has four roots but only two of these are positive and real. One of these approximates the active stable branch and the other the unstable branch. The two roots meet at the fold bifurcation joining these two branches, see 
i.e. the value of ki at which it can be guaranteed that inhibitor therapy be successful is determined principally (assuming rates of degradation and separation from receptors are comparable between AIP and inhibitor) by the rates of AIP production, mRNA transcription and separation of inhibitor molecules from receptors and of AgrA from the DNA binding site.
The only parameter of these which could be optimised, at least to an extent, through the design of the inhibitor molecule is the rate of separation of inhibitor molecules from the receptors, γi: minimising this parameter will decrease the value of ki at which inhibitor success can be guaranteed. Finally, we note that the activation level is determined solely by AIP production, mRNA transcription and degradation rates.
Inactive branch
The asymptotic approximations to the inactive branch are given bȳ
whereP ‡ is given at leading order by a physically-meaningful root of
As with equation (9), (11) While QS-induced transcription still features at leading order, basal transcription now also appears due to the high proportion of suppressed cells (seeM ‡ ∼vP ‡ + 1 in (10)). Similarly, we do not see the loss of transmembrane AgrD (S) as a result of AIP production in the leading-order behaviour of the inactive cells (the parameter kS does not feature in our approximation of S in (10)) because when the QS loop is repressed much less AIP is produced. It might seem logical to expect the activating binding reactions (represented by β and η) to be present in the leading-order behaviour of the active cells (i.e. in (8) and (9)) and the inhibitory binding reactions (βi) to be in that of the repressed cells (in (10) and (11)). However, even in an active state, the activating binding reactions do not come into the leading-order behaviour of these equations. We shall see that this is also the case for Model III, while Model II displays more unexpected behaviour in this respect. The lack of activating binding reactions at leading order in this model demonstrates that the QS circuit is sufficiently efficient that even when it appears as though the inhibitor molecules are dominating the behaviour, there can still be enough free receptors and AIP molecules to overcome the inhibition, and is consistent with the numerical solutions of Figures 12(b) (and 14(b) for Model III) where final AIP-bound receptor levels are much lower than those of inhibitor-bound receptor even when the cells reach an active state.
The location, (k ‡ iL ,P ‡ L ), of the lower fold bifurcation is given at leading order by
i.e. it is the same parameters governing the threshold value of ki below which inhibitor therapy is guaranteed to fail as those governing the threshold value of ki above which it is guaranteed to succeed; here, minimising γi will decrease the value of ki below which inhibitor is guaranteed to fail. In the inactive state, the proportion of active cells is determined (at leading order) simply by the rate of mRNA transcription: since the cell is inactive, the contributions of all other reactions are negligible.
Finally, notice that the approximation for i is the same regardless of whether the operon is active or inactive. We could thus simplify the model by approximating inhibitor concentration by ki/λi (the balance between its production and degradation), in particular if the focus of attention is on the steady states of the system.
Model II
Active stable branch and unstable branch
The asymptotic approximations to the active stable branch and unstable branch in Model II (where dephosphorylated AgrA is the activator) arē
Only the approximations forĀ † ,Ā † P andP † differ from Model I: here AgrA levels are governed by constitutive phosphorylation and activation, rather than translation and degradation as in Model I. The two positive real roots of (13) 
this, again, is very similar to Model I: the parameter groupings are the same with the exception of a dependence uponψA, the rate of constitutive phosphorylation of AgrA, in Model II. The level of inhibitor required to ensure downregulation of the agr operon (regardless of initial conditions) decreases with increasingψA. It would, therefore, be tempting to speculate that a Model II TCS would be stronger ifψA were smaller, but the result of this would be that increased levels of active AgrA would be present constitutively and not as a consequence of an active agr operon, thus defeating the purpose of the signal transduction system.
Inactive branch
The asymptotic approximations for the inactive stable branch of Model II arē
whereP ‡ andR ‡ are given at leading order by
eliminatingR ‡ gives a 7th order polynomial inP ‡ . Solving (15) and (16) produces only two meaningful roots, which join at the lower fold bifurcation; one of these provides an approximation to the inactive stable branch, see Figures 9(b) and 17(b) . It is possible to derive an expression for the location of the lower fold bifurcation as the solution to a 5th order polynomial, omitted for brevity.
As mentioned in §4.1, we now see some unexpected results in terms of the leading-order binding reactions. In the active state, only the inhibitory binding reactions played a part in the dominant behaviour of the system (see the dependence on γi in (12) and (13) . However, in the suppressed state, the activating binding reactions also appear at leading order (β, βi, γ and γi all play a role in (14)- (16)), whereas one might anticipate that, if they were going to arise,
we would see the activating binding reactions in the active state (i.e. in (12) and (13)). This can be understood if we bear in mind that the active and inactive systems capture the behaviour of the cells in the region of the fold bifurcations.
The upper fold bifurcation (on the active branch) represents the threshold level of inhibitor above which the inhibitor will certainly suppress the agr operon. The lower fold bifurcation (on the inactive branch) represents the threshold level of inhibitor below which the agr operon cannot be suppressed, i.e. where AIP dominates over inhibitor. Though nonintuitive at first, it is actually therefore reasonable that the activating binding reactions should appear at leading order on the lower branch, alongside the inhibitory ones. This behaviour is not seen in Models I or III because inhibitor levels are much larger in comparison to Model II, preventing the AIP-binding reactions from being dominant at leading order.
Model III
Active stable branch and unstable branch
We recall that this model requires additional variables to model the various phosphorylation states in which transmembrane AgrC can lie. Despite the extra variables, the leading-order reactions are very similar to Model I. Of those which are directly comparable, the only noteworthy difference is the appearance at leading-order of the loss of AIP-bound receptor through activation (in this model) rather than degradation (as happens in Model I). This difference makes the asymptotic approximations for certain variables in Model III appear quite different to the previous two models: where at leading orderP † is given by the roots of the cubic The upper fold bifurcation occurs at leading order at
kSv .
Thus the key parameters determining the threshold level of inhibitor above which inhibitor therapy will always suppress the agr operon are similar to those of Model I but, in addition, the combination of parameters representing the rate of AgrA activation (β/ηζ) in Model III will also affect this threshold level; the same applies to the approximation to the lower fold bifurcation, (21) , given below in §5.
Inactive branch
The following asymptotic expressions approximate the inactive branch for Model III:
where at leading orderP ‡ is given by the roots of the cubic
which has two positive real solutions. These two roots meet at the lower fold bifurcation and one follows the unstable branch, see Figures 9(c) and 18(b) . This lower fold bifurcation at leading order occurs at
The differences between the active and inactive leading-order reactions for Model III are equivalent to those discussed for Model I, namely the absence of basal transcription in the active cells and the loss of transmembrane AgrD through AIP production in the inactive cells. Additionally, as for Model I, the inhibitor concentration has the same asymptotic approximation for both the stable branches, thus providing a means by which to simplify the model.
We have been able to derive analytical expressions for the steady states of each of the models both when the agr operon reaches an active state and when inhibitor therapy is successful in forcing the operon into an inactive state. These expressions can be used for further study of the operon and, since the analysis reveals which parameters govern the threshold levels of inhibitor therapy, in the design of synthetic inhibitor molecules.
Discussion
We have examined the impact of a novel approach for combatting bacterial infection by developing models of three potential TCS cascades of the agr operon (the primary operon involved in the regulation of virulence factors in S. aureus and prevalent in many other pathogens), demonstrating the ease of testing biological hypotheses with mathematical models. In each case we saw bistable behaviour by the cells in response to the inhibitor therapy, making its success dependent on not only the rate, ki, at which inhibitor was introduced into the bacteria, but also the initial conditions of the system. The implication of this is that, unless ki can be increased sufficiently, this type of staphylococcal QS inhibition may only be useful as a therapy if it can be implemented in the early stages of infection, otherwise the autoinductive nature of the QS circuit is so efficient that the agr operon and thus the population of bacteria will still reach (or remain in) an active and virulent state regardless of inhibitor molecule concentration. This would clearly be a major drawback if QS inhibition were to be used as a therapy against bacterial infections and this complements the experimental results of [33] which demonstrate the importance of suppressing the agr operon in the initial stages of infection to prevent staphylococcal abscess formation in a mouse. Although downregulation could be guaranteed for large enough values of ki (so that the models lose their bistability), it is important to bear in mind that (aside from cost-effectiveness) there would presumably be a maximum amount of these inhibitor molecules that could be introduced to an infection site before they have adverse consequences upon the host.
Using numerical solutions we have shown that the dosage required for inhibitor therapy to be successful is heavily dependent upon the phosphorylation cascade of the TCS and have identified which of the three cascades is likely to be the most susceptible to inhibitor therapy and which is likely to be the most robust: the classical cascade, of the three, is the best equipped to evade inhibitor therapy and the Model II cascade (where AgrA is constitutively phosphorylated) is the weakest in this respect. It is clear that the Model II cascade is the least efficient of the three, since AgrA must be converted from its active form to an inactive state and then back to its active form, whereas AgrA in the other models simply goes from inactive to active. This would explain why Model II takes the longest to reach an active state, thus rendering it the most susceptible to inhibition. The Model III cascade also requires additional steps but these concern the transition between different phosphorylation states of the receptor, as opposed to the activator, hence making it more vulnerable to inhibition than Model I because its phosphorylation cascade is less efficient, but stronger than Model II because its inefficiency only indirectly affects activator levels (whereas that of Model II lies in the actual activator dynamics).
Given the large differences between the models, if the appropriate (even only semi-quantitative) experimental data were available, these investigations into the effect of inhibitor therapy on the different types of TCS cascade would provide an insight into which cascade is in operation in a particular strain of S. aureus or alternative species. Furthermore, if the TCS cascade mechanism of the strain of interest is already known, numerical investigations should help estimate the amount of inhibitor therapy required to suppress an infection successfully. Additionally, our asymptotic analysis in §4
indicates which parameters are primarily responsible for determining the efficacy of inhibitor therapy. Of these, only the rate of separation of inhibitor and receptor could be influenced through the design of the inhibitor. Interestingly, however, the rate of binding between inhibitor and receptor affects the leading-order behaviour of the cells at steady state only in one scenario (Model II when the cells were suppressed); according to our analysis, targetting the rate of separation should be much more effective in enhancing the potency of inhibitor therapy.
It is becoming increasingly clear that agr-like QS systems are employed by many Gram-positive bacteria, including a number of important pathogens. Although the focus of this study has been on S. aureus, the discovery of agr systems in the clostridial species has comparable significance: C. difficile has, in recent years, parallelled S. aureus in terms of nosocomial infections. Although the contribution of agr to virulence gene regulation in C. difficile and hence infection
are not yet known, agr systems regulate virulence factors in enterococci [34] , Listeria [8] and C. perfringens [6] . Hence the importance of understanding the agr operon extends far beyond its significance in S. aureus alone, not only for its medical implications but for fundamental questions of intra-and inter-species bacterial signalling. Similarly, TCSs are prevalent throughout the bacterial kingdom, and while we have chosen to study TCSs in the context of the agr operon, the results (for instance in comparing the robustness of the three TCS cascades) are likely to be transferable across different systems.
Appendix A: Nondimensionalisation and initial conditions
For Models I and II we employ the same nondimensionalisations in order to make easier comparisons. Due to the extra variables in Model III we need to adapt the nondimensionalisation so that it is as consistent as possible with the first two.
We start by describing the totally down-regulated steady states of the three models. This is what would arise if no AIP were produced (k = 0) and no inhibitor molecules are present (ki = 0), so that QS has absolutely no effects. For
Model I these are given bỹ
whereX denotes the completely down-regulated steady state of variable X, i.e. where protein levels are directed only by basal mRNA transcription and not by agr-induced transcription. It is important to remember that these are not the steady states of a system where inhibitor molecules have suppressed the agr operon.
Those which change for Model II arẽ
,ÃP = N ψAκm δM ((ψA + δA)(µ + δA P ) − ψAµ) ,
Those which differ from (22) for Model III arẽ
Models I and II
We now use (22) to nondimensionalise the relevant variables (namely mRNA and all unphosphorylated proteins, with the exception of phosphorylated AgrA in Model II, since these are the only species present in a totally down-regulated cell).
Hence we set
for X = B, C, D and Y = T, R, S respectively. The remaining nondimensionalisations are chosen to simplify the corresponding equations as much as possible, namely to set the coefficients of basal mRNA transcription, AIP-receptor binding, AgrA activation and phosphorylated AgrA binding to the promoter site in certain equations to unity. They are given by
P already being dimensionless. Time is thus scaled with δM , the rate of mRNA degradation. Dimensionless parameters are introduced according to
and
whereX is the initial condition of X given by (22) , for X = A, T, R, S.
We assume that protein degradation rates are negligible in comparison to the dilution rate so, since δX = λX + r we set all the parameters in (27) to be equal. By additionally assuming that AgrB and AgrC are taken into the membrane at the same rate and that AgrD is anchored at this same rate, we can do the same in (28). Thus we take
Dropping ′ 's we get the nondimensional models represented by Figures 6 and 7 . The initial conditions are given by the dimensionless natural down-regulated steady state which for Model I is simply
Those which change for Model II are
and differ because constitutive AgrA phosphorylation means both A and AP will be present in a down-regulated cell and some induction of the operon will occur (making P non-zero also in a down-regulated state) in response to the (presumably low) levels of AgrA. These are used as initial conditions in the numerical simulations illustrated by Figures
12(a) and 13(a).
We nondimensionalise the relevant variables using the down-regulated steady states of this model (rather than those of Model I) and choose the remaining nondimensionalisations to ensure the equivalent terms have coefficient unity as in the previous two models.
The nondimensional variables which alter from (25) and (26) are
The nondimensional parameters which differ from (27)- (30) are
Dropping ′ 's the resulting nondimensional model is illustrated by Figure 8 . The initial conditions (again, the nondimensional natural down-regulated steady states) which change from (31) (i.e. Model I) are
These are used as initial conditions in Figure 14 (a).
Appendix B: Derivation of the asymptotic approximations
We here describe the derivation of our asymptotic approximations (introduced in §3 and given explicitly in §4) to the steady-state curves of Figure 9 . In each case, the appropriate scalings of ki are chosen in order to capture the requisite information from the asymptotic analysis in order to represent each section of the curve. These (distinguished-limit) scalings reflect how sensitive each TCS cascade is to inhibitor therapy and are provided in Table 4 . We recall that our small parameter ǫ represents the ratio of the rate of basal mRNA transcription to that of QS-controlled transcription.
Notice that considerably larger scalings of ki are required in Model I due to the fact that it is the least susceptible to inhibition of the three models.
For each model we obtain two sets of scalings which cover the full solution curve: one represents both the active stable branch and the unstable branch, while the other incorporates the inactive stable branch and the lower fold bifurcation; in each case there is, in the usual way, an intermediate regime in which the two approximations overlap (i.e. furnish the same solutions at leading order) and we also derive these regimes here. Table 4 : The distinguished scalings required for the asymptotic approximation to the active and inactive sections of the solution curves illustrated in Figure 9 (the former also incorporate the unstable branch). The scalings required for
are the same as those given for M (τ ). The variables R P and R * appear in Model III only.
produce the asymptotic approximation to the active and unstable branches are denoted by X † ; when they are scaled to approximate the inactive branch we use X ‡ . The steady state approximations for each variable X are denotedX † and X ‡ . Since, in the steady state,M ≡B ≡C ≡D ≡T (mRNA concentration and natural degradation, which we have assumed to occur at the same rate for all proteins, are the only reactions influencing the levels of these proteins), we eliminate B, C, D and T in favour of M in the remainder of this appendix.
Model I
Active stable branch and unstable branch
Inactive branch
Using the scalings from Table 4 we derive the steady-state equations to represent the stable branch which represents inactive cells. Equations (39),(40),(43) and (44) also hold for this branch; the equations which change are
Solving the leading-order terms of (39), (40), (43), (44) and (46)- (51) gives us the asymptotic approximations on the inactive stable branch, i.e. (10) and (11) . We note that the 'near-field' limit (k † i → 0) of (9) and the 'far-field' one (k ‡ i → ∞)
We manipulate the leading-order terms to obtain the approximations to the active and unstable branches of the solution curves, i.e. (12) and (13) .
For the inactive branch we again find that some of the steady state equations do not alter from Model I, namely (43), (44), (47), and (48). The remaining equations are given by
The leading-order terms of these equations allow us to calculate the approximations to the inactive stable branch, i.e. (14)- (16) . The region where both (13) and this approximation to the inactive branch hold, i.e. k †
We have that (36) and (38)-(40) all also hold for Model III. In addition we have
The dominant terms give (17) and (18), i.e. the asymptotic approximations to the active stable and unstable branches for Model III.
Equations (39), (40) and (46)-(48) all also apply for this model. Those which differ are
As before, the leading-order terms can be rearranged to give (19) and ( 13 Selected numerical solutions to the nondimensional Model II using the parameters from Table 3 . In ( 
